holding company Blackhawk Growth Corp.BLRZFs subsidiary MindBio Therapeutics Pty Ltd shared the positive data collected from it is Phase 1 clinical trials of LSD microdosing Formulation in 80 healthy participants.

A practical summary of the results collected at this stage: microdoses of LSD have shown no serious side effects – although nervousness may occur in some patients – and the increase in energy, well-being, happiness, creativity and connectedness suggests antianhedonic properties to improve the management of patients with depression, home microdosing studies appear feasible and practical , and subtle dose measurement and adjustment could optimize the treatment regimen.

MindBio co-founder Justin Hanka stated that the positive data from these Phase 1 clinical trials is a validation of the Company’s investment in advancing proprietary LSD development into Phase 2 clinical trials.

These following studies will evaluate the effectiveness of the compound in treating patients depression (MDD) along with late-stage cancer patients who are experiencing existential hardship.

“We are pleased with the positive results of our clinical trials and the progress we are making in commercializing psychedelic medicines and finding more effective medical treatments for mental illness,” said Fred Pels, CEO of Blackhawk.

The study and results

Of the 136 total participants screened for the study, 80 were randomized. Specifically, healthy male volunteers were randomized into LSD 10 μg (0.01 mg) and placebo groups and received 14 doses of each every three days for six weeks.

A total of 1102 microdoses (LSD/placebo) were administered with 100% adherence to therapy and without any substance change. The first doses were administered under supervision, while the remaining doses were self-administered.

Safety data, blinding, daily questionnairesExpectation, and before and after the intervention psychometric and cognitive tasks were measured…